Literature DB >> 29996131

Increasing the Sensitivity of Functional Status Assessment in the Preclinical Range (Normal to Mild Cognitive Impairment): Exploring the IADL-Extended Approach.

Robert Fieo1, Yaakov Stern2.   

Abstract

BACKGROUND/AIMS: Dementia exhibits an insidious onset consisting of cognitive, behavioral, and functional impairment. We explored a functional continuum that extends assessment beyond the clinical instrumental activities of daily living (IADL) range and into advanced activities of daily living.
METHODS: We examined the predictive power (Cox regression; n = 2,471) of a unidimensional IADL-extended (IADL-x) scale for incident mild cognitive impairment (MCI). We also examined "time to MCI" as an outcome measure.
RESULTS: Each additional task endorsed on the IADL-x hierarchy (e.g., endorsing participation in 6 vs. 5 activities) resulted in a 10% reduction in MCI risk (HR 0.90, 95% CI 0.85-0.94, p < 0.001). For the fully adjusted model the risk reduction dropped to 6%. The odds of incident MCI within 2 years (for those below the median IADL-x total score) was 2.5 times higher (OR 2.60, 95% CI 1.52-4.4, p < 0.001) and 2 times higher for incident MCI within the next 5 years (OR 1.93, 95% CI 1.76-3.2, p < 0.01).
CONCLUSION: The IADL-x metric appears to be a valid approach for determining the risk of MCI based on one's position along a formal hierarchy of function.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Cognition; Functional status; Mild cognitive impairment; Preclinical dementia

Mesh:

Year:  2018        PMID: 29996131     DOI: 10.1159/000487632

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  1 in total

1.  How Well Does the Brief Interview for Mental Status Identify Risk for Cognition Mediated Functional Impairment in a Community Sample?

Authors:  Timothy S Marks; Gordon M Giles; Muhammad O Al-Heizan; Dorothy F Edwards
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.